The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
June 19th 2025
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Mismatch Repair Deficiency an Ideal Marker to Initiate Precision Care in CRC
July 19th 2016Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA mismatch repair.
Read More